Live virtual fireside chat - investors, advisors, and life sciences analysts invited to attendKing of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a

<p>Live virtual fireside chat - investors, advisors, and life sciences analysts invited to attend</p><p>King of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PHIO">PHIO</a>) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL<sup>&#174;</sup> gene silencing technology to eliminate cancer.  Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Harvey Briggs, Chief Communications Officer, Force Family Office. Joining them will be James Cardia, Ph.D., who will explore siRNA therapy and skin cancer treatments. </p><p>"We are excited to take part in this fireside chat with Force Family Office," said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals. "Dr. Jim Cardia will discuss the future direction of siRNA oncology and highlight how our INTASYL&#174; siRNA program represents a differentiated and innovative approach to immuno-oncology."</p><p><b>DATE:  Monday June 29, 2026</b></p><p><b>TIME:   12 PM EDT</b></p><p><b>REGISTRATION LINK:  </b><a href="https://api.newsfilecorp.com/redirect/kXQYXsVYe0"><b>PHIO Pharma - Force Family Office</b></a></p><p><b>About Phio Pharmaceuticals Corp.</b></p><p>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PHIO">PHIO</a>) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL<sup>&#174;</sup> siRNA gene silencing technology to eliminate cancer. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical development program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) evaluated PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.</p><p>For additional information, visit the Company's website, <a href="https://api.newsfilecorp.com/redirect/B5OL5hpPxY" target="_blank">www.phiopharma.com</a>.  </p><p><b>Forward-Looking Statements</b></p><p><i>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements, which include statements, among other things, regarding the anticipated benefits of our INTASYL&#8482; RNAi platform, the results from our ongoing clinical trials, our expectations that our cash runway will extend into the first half of 2027, our expectations regarding timing of FDA submissions intended to propose and seek guidance for next steps in clinical study design for PH-762, our expectations that such FDA submissions and any related FDA meetings will clarify next steps in advancing the PH-762 development program, details regarding our planned non-clinical toxicology study, and our ability to support ongoing clinical development, operational requirements and strategic initiatives with the capital we currently have on hand, are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact of future FDA interactions on the development of our product candidates; the impact to our business and operations by inflationary pressures; recession fears; the development of our product candidates, results from our nonclinical, preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those risks identified in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the U.S. Securities and Exchange Commission. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.</i></p><div id="contactInfo"><p><b>Contact:<br />Phio Pharmaceuticals Corp.<br /></b>Jennifer Phillips: <a href="mailto:jphillips@phiopharma.com" target="_blank">jphillips@phiopharma.com<br /></a>Corporate Affairs </p></div><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/10407/302679_8556451774eecaf9_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/5WzeWU5WEe">https://www.newsfilecorp.com/release/302679</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/302679/197" alt="" /></p>

PHIO

Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026

PHIO to discuss INTASYL strategy and 1H2027 cash runway at fireside chat

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Live virtual fireside chat - investors, advisors, and life sciences analysts invited to attendKing of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Phio Pharmaceuticals announced a live fireside chat on June 29 with Force Family Office, featuring CEO Bitterman and Dr. James Cardia to discuss INTASYL siRNA oncology and the PH-762 program targeting PD-1. The company also notes its cash runway extends into the first half of 2027 and outlines potential FDA steps for PH-762. No new clinical data was released, making this primarily a visibility catalyst.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>PHIO to participate in fireside chat with Force Family Office on June 29, 2026.</li><li>Dr. Cardia to discuss INTASYL siRNA and PH-762 targeting PD-1 in skin cancers.</li><li>Company states cash runway extends into first half of 2027; potential financing discussions ahead.</li><li>No new clinical data; event primarily increases investor visibility and branding.</li><li>Forward-looking statements warn results may differ due to FDA, funding, and market factors.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Phio Pharmaceuticals Corp. (PHIO)</strong>: Clinical-stage siRNA company; event-driven visibility but no new data.</li><li><strong>Force Family Office (N/A)</strong>: Organizer of the fireside chat; potential influence on investor interest but no disclosed funding terms.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This is a Corporate Developments update centered on an investor event and cash runway guidance. It signals visibility and funding considerations rather than new clinical data, which can modestly influence sentiment and liquidity expectations.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Event-driven fireside chat on June 29 could trigger short-term volatility in PHIO.</li><li>Cash runway extension into 1H2027 lowers near-term liquidity concerns.</li><li>PH-762 PD-1 program has no new data in this release; no price catalyst.</li><li>FDA submission timing and trial design updates could shift sentiment if announced.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>PR dated June 25, 2026.</li><li>DATE: Monday June 29, 2026; 12 PM EDT.</li><li>PHIO leads with INTASYL siRNA platform; PH-762 targets PD-1 in skin cancers.</li><li>PHIO cash runway extended into 1H 2027.</li><li>No new clinical data released in this release.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term, expect modest upside from event-driven visibility; real alpha requires PH-762 data or FDA milestones.</p>
  </section>
</section>


<p>Live virtual fireside chat - investors, advisors, and life sciences analysts invited to attend</p><p>King of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PHIO">PHIO</a>) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL<sup>&#174;</sup> gene silencing technology to eliminate cancer.  Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Harvey Briggs, Chief Communications Officer, Force Family Office. Joining them will be James Cardia, Ph.D., who will explore siRNA therapy and skin cancer treatments. </p><p>"We are excited to take part in this fireside chat with Force Family Office," said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals. "Dr. Jim Cardia will discuss the future direction of siRNA oncology and highlight how our INTASYL&#174; siRNA program represents a differentiated and innovative approach to immuno-oncology."</p><p><b>DATE:  Monday June 29, 2026</b></p><p><b>TIME:   12 PM EDT</b></p><p><b>REGISTRATION LINK:  </b><a href="https://api.newsfilecorp.com/redirect/kXQYXsVYe0"><b>PHIO Pharma - Force Family Office</b></a></p><p><b>About Phio Pharmaceuticals Corp.</b></p><p>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PHIO">PHIO</a>) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL<sup>&#174;</sup> siRNA gene silencing technology to eliminate cancer. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical development program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) evaluated PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.</p><p>For additional information, visit the Company's website, <a href="https://api.newsfilecorp.com/redirect/B5OL5hpPxY" target="_blank">www.phiopharma.com</a>.  </p><p><b>Forward-Looking Statements</b></p><p><i>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements, which include statements, among other things, regarding the anticipated benefits of our INTASYL&#8482; RNAi platform, the results from our ongoing clinical trials, our expectations that our cash runway will extend into the first half of 2027, our expectations regarding timing of FDA submissions intended to propose and seek guidance for next steps in clinical study design for PH-762, our expectations that such FDA submissions and any related FDA meetings will clarify next steps in advancing the PH-762 development program, details regarding our planned non-clinical toxicology study, and our ability to support ongoing clinical development, operational requirements and strategic initiatives with the capital we currently have on hand, are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact of future FDA interactions on the development of our product candidates; the impact to our business and operations by inflationary pressures; recession fears; the development of our product candidates, results from our nonclinical, preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those risks identified in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the U.S. Securities and Exchange Commission. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.</i></p><div id="contactInfo"><p><b>Contact:<br />Phio Pharmaceuticals Corp.<br /></b>Jennifer Phillips: <a href="mailto:jphillips@phiopharma.com" target="_blank">jphillips@phiopharma.com<br /></a>Corporate Affairs </p></div><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/10407/302679_8556451774eecaf9_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/5WzeWU5WEe">https://www.newsfilecorp.com/release/302679</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/302679/197" alt="" /></p>

Phio Pharmaceuticals announced a live fireside chat on June 29 with Force Family Office, featuring CEO Bitterman and Dr. James Cardia to discuss INTASYL siRNA oncology and the PH-762 program targeting PD-1. The company also notes its cash runway extends into the first half of 2027 and outlines potential FDA steps for PH-762. No new clinical data was released, making this primarily a visibility catalyst.

phio-pharmaceuticals-announces-how-sirna-therapy-can-change-the-course-of-cancer-treatment-in-a-fireside-chat-with-force-family-office-on-monday-june-29-2026

Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News